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VIROLOGIC AND CLINICAL OUTCOMES OF HEPATITIS B VIRUS INFEC-
TION IN RECIPIENTS UNDERGOING UNRELATED-DONOR HEMATOPOI-
ETIC STEM CELL TRANSPLANTATION
Luo, Y., Hu, Y., Tan, Y., Lai, X., Shi, J., He, J., Zheng, G., Zheng, W.,
Xie,W., Cai, Z., Huang,H. The 1st AffiliatedHospital, ZhejiangUniver-
sity, School of Medicine, Hangzhou, Zhejiang, China
Introdution:Hepatitis B virus (HBV) infection in recipients may be
associated with hepatitis and increased nonrelapse mortality (NRM)
following unrelated-donor allogeneic hematopoietic stem cell trans-
plantation (allo-HSCT). China is an endemic area for HBV infec-
tion. It is especially significant to clarify the true impact of HBV
on outcomes of allo-HSCT as well as preventive and treatment strat-
egies in this special population. In the current study, we performed
a retrospective analysis of the virologic and clinical outcomes of
HBV infection in recipients undergoing allo-HSCT with active
anti-HBV prophylaxis or treatment from seronegative unrelated
donors for HBV.
Patients and Methods: Between 1998 and May 2009, 222 patients
underwent unrelated donor allo-HSCTwere enrolled. Patient infor-
mation was collected from the BMT database. Anti-HBV therapy
consisted of lamivudine or entecavir for HBsAg positive recipients
before HSCTwhile marrow harvest and HSCTwere performed un-
til recipient’s serum HBV-DNA became undetectable. HBV-DNA
was isolated from serum with the QIAmpt blood kit and quantita-
tively measured using a kinetic fluorescence detection system. All
of the patients were followed up in out-patient department weekly
and HBV serology were detected once every month.
Results: Before transplantation, 17 patients who were positive for
HBsAg and received lamivudine or entecavir prophylaxis were re-
garded as group 1. There was 1 case of reactivation of HBV in this
group and 8 cases became negative forHBsAg and posive forHBsAb.
One hundred and fifty four patients who were negative for HBsAg
and anti-HBc before allo-HSCT were regarded as a control group.
Fifty one patients who were negative for HBsAg and positive for
anti-HBc were regarded as group 2. In the control group none was
identified as positive for HBsAg after HSCT while in group 2, 2 pa-
tients developed hepatitis, thus indicating reverse seroconversion.
For these 2 patients lamivudine were administered for anti-HBV
therapy and 1 patients died of HBV-related hepatic failure. There
were no significant differences in overall survival(OS), and incidence
of acute graft-versus-host disease(GVHD) and chronic GVHD
among the 3 groups.
Conclusion:Our data suggest that HBV infection in the recipient at
the time of transplantation does not seem to adversely affect outcome
after allo-HSCT with active anti-HBV prophylaxis or treatment.
HBV infection in the recipient is not a contraindication of allo-
HSCT.411
FLAGELLIN REDUCES GVHD THROUGH EARLY IMMUNOSUPPRESSION
INDUCED BY THE FLAGELLIN-TLR5 IMMUNE INTERACTION OF HOST
CELLS IN ALLOGENEIC HSCT RECIPIENTS
Hossain, M.S.1, Gewirtz, A.T.2, Roback, J.D.2, Waller, E.K.1 1Emory
University, Atlanta, GA; 2Emory University, Atlanta, GA
We previously showed that flagellin (Fla) significantly reduced
GvHD inH-2K/H-2bHSCTmodel and had better long-term sur-
vival. Here, we reported the mechanisms by which Fla reduces
GvHD using similar HSCT model and also B6 BM / B6TLR5
knock out (KO) and KO BM/B6 radiation chimeras. We hypoth-
esized that flagellin-TLR5 binding in the host gut epithelium will be
responsible to reduce GvHD. To determine the flagellin effects on
early days of transplant, Fla-treated (50-mg/mouse i.p 3 hrs before ir-
radiation and 24 hrs after transplant) B6 recipients of 3x106 spleno-
cytes and 5x106 TCDBM cells fromH-2K donors were sacrificed on
day 4 and 10 after post transplant. Splenocytes were analyzed by
FACS. Fla-treated recipients had significantly lower numbers of cells
per spleen compared to controls [p5 0.002] on day 4 post transplant
but not on day 10 [p5 0.43] post-transplant. Accordingly, the num-
bers of donor spleen-derivedCD4 andCD8T cells per spleen in Fla-
treated recipients were significantly lower compared to PBS-treatedrecipients on day 4 post transplant. The early activation status of do-
nor T cells in the spleen of Fl-treated recipients was also found sig-
nificantly lower compared to controls. Next, we addressed our
hypothesis by doing similar experiments using radiation chimeras.
Radiation chimeras were generated by transplanting 10x106 BM cells
from B6 and/or KO donors to 11Gy irradiated B6 or KO recipients.
B6/KO, KO/B6, B6/B6, KO/KO radiation chimeras were
again irradiated with 9.0Gy and transplanted with 3x106 H-2K sple-
nocytes and 5 x 106TCD BM 12 weeks later. Each group received
two doses of Fla or PBS i.p. Survival and weight loss were deter-
mined. Fla-treated B6/B6 radiation chimeras (TLR5+ donor and
host hematopoietic and host epithelial cells) survived 100% with
only mild GvHD (12% weight loss at day 79 post transplant). 50%
of Fla-treated B6/KO (TLR5+ donor hematopoietic cells) and
40% of KO/ B6 (TLR5+ host hematopoietic and epithelial cells)
chimeras survived with 15% and 18% weight loss, respectively. All
the Fla-treated KO/ KO recipients died within 65 days post trans-
plant. On the other hand, all 4 groups of PBS-treated control recip-
ients died or were sacrificed due to GvHD-associated weight loss
exceeding 25%.
Conclusion: Flagellin reduces GvHD by suppressing the activities
of donor T cells within 4 days post-transplant. The early immuno-
suppression may be the result of Fla-TLR5 immune interaction in
the host epithelium that reduces GvHD.412
USE OF RABBIT ANTI-THYMOCYTE GLOBULIN FOR CONDITIONING IN
MATCHED UNRELATED DONOR HEMATOPOIETIC CELL TRANSPLANTA-
TION PROVIDES COMPARABLE DOSE DEPENDANT OUTCOMES TO
MATCHED RELATED DONOR RECIPIENTS
Portier, D.A., Catherine, R.H., Fletcher, D.R., Sabo, R., Rabie, S.,
Clark, W.B., Manjili, M., Tessier, J.M., Chung, H.M.,
McCarty, J.M., Toor, A.A. Virginia Commonwealth University,
Richmond, VA
Rabbit Anti-thymocyte globulin (ATG) is used as prophylaxis
against graft vs. host disease (GVHD) following allogeneic hemato-
poietic cell transplant (HCT). At our institution ATG (7.5 or 10mg/
kg infused over three days from day -3 to day -1) is used in the con-
ditioning of matched unrelated donor (MUD) transplant recipients
but not in matched related donor (MRD) recipients. We retrospec-
tively studied post transplant outcomes betweenMUDandMRD re-
cipients with acute leukemias or myelodysplasia to study the impact
ATGmight have on post transplant outcomes. Patients transplanted
between 2004 and 2009 were included in the study (n5 98). Fifty pa-
tients underwent MUD HCT and received ATG (ATG group); 48
in the MRD group did not receive ATG (no ATG group). There
were no significant differences between the groups in day 100 mor-
tality (RR 0.57, 95% CI 0.23, 1.4; P 5 0.24), acute GVHD
(aGVHD) (RR 1.74; 95% CI 0.9, 3.2; P 5 0.07), or relapse (RR
1.07; 95% CI 0.45, 2.39; P 5 0.87). Chronic GVHD (cGVHD) in-
cidence was significantly lower in the ATG group when compared
with the no ATG group (RR 0.22, 95% CI 0.09-0.58; P 5
0.0018). At a median follow up of 36 months in the entire cohort,
50% patients are alive in the ATG group with a median survival of
36 months, and 63% of the patients are alive in the no ATG group
(Log Rank P 5 0.13). The 2-year survival for the ATG vs. no
ATG cohorts is 51% (95% CI, 30%, 72%) vs. 63% (95% CI,
38%, 82%) (Log-Rank P 5 0.2145). To further explore the effect
of ATG dose on post transplant outcomes, patients who received
10 mg/kg dose of ATG (52% of ATG recipients) were compared
to those who received 7.5 mg/kg. Relapse rate, as well as acute and
chronic GVHD rate was comparable in the two groups, however
all causemortality in the 10mg/kgATGdose groupwas significantly
higher (RR 0.54, 95% CI 0.3, 0.96; P 5 0.03) mostly due to infec-
tions. We conclude that the addition of ATG to the conditioning
regimen of patients undergoing MUD HCT reduces the risk of de-
veloping chronicGVHD, resulting in overall survival rates which are
comparable to MRD HCT recipients. Outcomes were superior
when an ATGdose of 7.5mg/kg was used in our patients.We submit
that ATG use in conditioning MUDHCT recipients will yield ben-
efit beyond recently adopted standards of stringent HLA matching
and improved supportive care.
